ALC News & Events

The firm states: "Alcon (ALC) and RxSight (RXST) announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses, or PCIOLs. Under the collaboration, the companies will be innovating on their respective platforms - RxSight's post-operative light-adjustable technology and Alcon's PCIOL optical designs - and combining them to create a co-developed technology that enables surgeons to fine-tune visual outcomes for their cataract patients who choose a PCIOL. As part of the agreement, RxSight will receive a $60 million upfront payment to begin development. RxSight could receive up to an additional $140 million in payments as development and regulatory milestones are met. Under the agreement, Alcon will lead global commercialization, while RxSight will be responsible for development and manufacturing and receive royalties on net sales."

Alcon (ALC) and RxSight (RXST) announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses, or PCIOLs. Under the collaboration, the companies will be innovating on their respective platforms - RxSight's post-operative light-adjustable technology and Alcon's PCIOL optical designs - and combining them to create a co-developed technology that enables surgeons to fine-tune visual outcomes for their cataract patients who choose a PCIOL. As part of the agreement, RxSight will receive a $60M upfront payment to begin development. RxSight could receive up to an additional $140M in payments as development and regulatory milestones are met. Under the agreement, Alcon will lead global commercialization, while RxSight will be responsible for development and manufacturing and receive royalties on net sales.